London, United Kingdom
Centauri Therapeutics is a UK-based biotechnology company established in 2015, specializing in the development of innovative molecules for combatting life-threatening diseases. The company's proprietary Alphamer technology leverages "programmable immunity" by redirecting naturally occurring antibodies to specific pathogens to combat infections. Alphamers have demonstrated the ability to effectively redirect pre-existing antibodies to bacteria and trigger an immediate antibacterial immune response, thus aiding in clearing the infection. The company's intellectual property includes specific leads and platform chemistry, safeguarded by a family of granted patents and applications.
Centauri Therapeutics recently secured a £24.00M Series A investment on 16 February 2022, with prominent investors such as Novo Holdings, Evotec, Wren Capital LLP, Kent Life Science LLP, Boehringer Ingelheim Venture Fund, and Animatrix Founders participating in the funding round. With a focus on revolutionizing immunotherapy for infectious diseases, Centauri Therapeutics is poised for significant growth and impact within the biotechnology and healthcare industries.
